Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Formycon AG

Start price
Target price
Perf. (%)
€75.00
12.07.22
-
12.07.23
-23.87%
12.07.23

buy
MicroVision Inc

Start price
Target price
Perf. (%)
€6.25
10.06.23
€7.00
10.06.24
-38.41%
10.07.23

Fair valuation
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
buy
Esperion Therapeutis.Inc.

Start price
Target price
Perf. (%)
€1.25
25.06.23
-
25.06.24
15.66%
09.07.23

Could be worthwhile Investment >10% per year
buy
Intellia Therapeutics Inc

Start price
Target price
Perf. (%)
€63.18
09.07.22
-
09.07.23
-41.45%
09.07.23

buy
MacroGenics Inc.

Start price
Target price
Perf. (%)
€4.46
29.05.23
-
29.05.24
1.35%
08.07.23

Risky Investment
buy
Fate Therapeutics Inc.

Start price
Target price
Perf. (%)
€4.45
11.06.23
-
11.06.24
3.69%
27.06.23

Could be very worthwhile Investment >20% year
buy
Esperion Therapeutis.Inc.

Start price
Target price
Perf. (%)
€1.29
11.06.23
-
11.06.24
-2.64%
24.06.23

Could be worthwhile Investment >10% per year
buy
Axsome Therapeutics Inc

Start price
Target price
Perf. (%)
€60.00
08.09.22
€80.00
31.12.24
35.00%
24.06.23

Could be very worthwhile Investment >20% year
buy
Medigene AG

Start price
Target price
Perf. (%)
€1.92
14.06.23
€2.00
14.06.24
-2.61%
24.06.23

Could be very worthwhile Investment >20% year
Very capable Management
Good culture
Little innovation
buy
Esperion Therapeutis.Inc.

Start price
Target price
Perf. (%)
€1.53
22.05.23
-
22.06.23
-17.49%
23.06.23

Could be worthwhile Investment >10% per year
buy
co.don AG

Start price
Target price
Perf. (%)
€1.41
17.06.21
-
17.06.23
-13.17%
17.06.23

Revenue growth >5% per year expected
Innovative
Future proof or reliable business model
Could be very worthwhile Investment >20% year
Trevena Inc.

Start price
Target price
Perf. (%)
€1.21
16.05.23
-
16.05.24
-17.50%
12.06.23

buy
Corvus Pharmaceuticals Inc

Start price
Target price
Perf. (%)
€2.40
15.05.23
-
15.05.24
30.00%
12.06.23

Probably not worthwhile Investment
Verastem Inc.

Start price
Target price
Perf. (%)
€13.94
30.05.23
-
30.05.24
-19.06%
11.06.23

Could be very worthwhile Investment >20% year
Trevena Inc.

Start price
Target price
Perf. (%)
€1.30
31.05.23
-
31.05.24
-23.04%
11.06.23

buy
Poxel S.A.

Start price
Target price
Perf. (%)
€2.49
20.08.22
-
20.08.23
-75.54%
07.06.23

Could be worthwhile Investment >10% per year
buy
Valneva SE

Start price
Target price
Perf. (%)
€10.23
09.08.22
€14.00
09.08.23
-46.91%
30.05.23

Small cyclical dependencies
Below average Marketposition
Few uniques
Nuwellis Inc.

Start price
Target price
Perf. (%)
€1.26
31.08.22
-
31.08.23
-90.95%
29.05.23

Could be very worthwhile Investment >20% year
buy
Fate Therapeutics Inc.

Start price
Target price
Perf. (%)
€4.79
15.05.23
-
15.05.24
-1.17%
29.05.23

Could be very worthwhile Investment >20% year
buy
Bone Therapeutics S.A.

Start price
Target price
Perf. (%)
€0.27
02.06.22
€0.50
02.06.23
-59.20%
28.05.23

Could be worthwhile Investment >10% per year
buy
Motus GI Holdings Inc.

Start price
Target price
Perf. (%)
€0.88
17.05.23
-
17.05.24
-25.40%
27.05.23

Could be worthwhile Investment >10% per year
Capable Management
Very good company culture
Little innovation
buy
Fate Therapeutics Inc.

Start price
Target price
Perf. (%)
€21.75
22.05.22
-
22.05.23
-78.27%
22.05.23

buy
Affimed N.V.

Start price
Target price
Perf. (%)
€3.34
22.05.22
-
22.05.23
-68.81%
22.05.23

Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€3.19
11.06.22
€1.60
11.06.23
84.40%
19.05.23

Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
Promis Neurosciences Inc.

Start price
Target price
Perf. (%)
€4.22
11.03.23
€4.60
11.03.24
18.48%
19.05.23

ROE lower than 10% per year
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected